Mar. 13 at 6:58 PM
eXoZymes (Nasdaq:
$EXOZ) announced that Chief Commercial Officer Damien Perriman will present at the MISTA Symposium Healthspan event in San Francisco on March 18, 2026.
eXoZymes is a B2i Digital Featured Company. See their full profile at https://b2idigital.com/exozymes-1.
Perriman’s presentation will focus on scaling production of NCT, a plant-derived molecule with potential applications in both nutraceutical and pharmaceutical markets. NCT has attracted attention for its possible role in metabolic health, specifically how the body converts fuel into energy. Its rarity in nature has historically limited commercial development, but eXoZymes is working to change that through its exozyme platform, which uses AI-designed enzyme cascades operating outside living cells to enable scalable production.
The MISTA Symposium Healthspan event brings together leaders from the food, nutrition, and health industries to explore how scientific advances can support healthier aging and metabolic resilience.
Perriman commented: “When it comes to health, a lot of people feel frustrated because they’re trying - but nothing seems to work. They feel trapped between conflicting advice and solutions that are difficult to sustain. But now there’s hope - what makes NCT so exciting is that it focuses on the underlying problem: how the body converts fuel into energy. By addressing that fundamental process, we believe it could represent a meaningful new approach to metabolic health. We’re excited to share how advances in cell-free enzyme engineering are making it possible to bring this rare natural compound into scalable production and explore its potential across nutrition and medicine.”
Read the full press release here: https://exozymes.com/blog/2026-mista-perriman
eXoZymes is a Los Angeles, California-based biotechnology company pioneering cell-free biomanufacturing through AI-engineered enzymes that transform sustainable feedstock into nutraceuticals, medicines, and essential chemicals. The company’s proprietary exozyme platform offers a scalable, eco-friendly alternative to traditional petrochemical processes, with technology validated through publications in Nature Communications and Nature Chemical Biology. Recently demonstrating gram-scale production of NCT with over 99% purity in just five months, eXoZymes focuses on high-value products including active pharmaceutical ingredients, nutraceuticals, and sustainable aviation fuel.
eXoZymes is led by an experienced management team including Michael Heltzen, CEO; Damien Perriman, CCO; Dr. Tyler Korman, CSO and Co-founder; Dr. Paul Opgenorth, VP of Development and Co-founder; Fouad Nawaz, VP of Finance; Dr. Zachary Karl, VP of Business Development; Lasse H. Görlitz, VP of Communications; and Amy Lunzer, Chief of Staff.
To learn more about eXoZymes Inc., visit https://exozymes.com. For investor inquiries, visit https://exozymes.com/investor.
Disclosure: David Shapiro, Chief Executive Officer of B2i Digital, personally purchased in the open market and currently owns shares of unrestricted EXOZ stock, in line with B2i Digital’s practice of investing alongside its Featured Companies. This post is not intended to solicit the sale of EXOZ or any security, and it is not intended to offer any opinion on EXOZ as an investment. Conduct your own research and consult with your own professional advisors prior to making any investment decisions. See the complete disclosure in the Risks and Disclosures section of https://b2idigital.com/disclaimer.
$EXOZ $BIOTECH $AI $SYNBIO $LONGEVITY.X
$METABOLICHEALTH $NASDAQ